TL;DR
The CDC’s 2026 antimicrobial resistance report identifies 19 pathogens as urgent, serious or concerning threats, with six more on a watch list. The agency estimates the listed pathogens cause 9.7 million U.S. infections and 50,800 deaths annually; four drug-resistant pathogens are classified as urgent threats.
The CDC’s 2026 antimicrobial resistance report lists 19 pathogens as urgent, serious or concerning threats and estimates that they collectively cause 9.7 million infections and 50,800 deaths in the United States each year. Four drug-resistant pathogens received the agency’s top “urgent” classification, while six others were placed on a watch list.
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The four pathogens at the top of the CDC’s revised drug-resistant threat list are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The report categorizes pathogens by threat level, with “urgent” indicating the highest tier in this assessment. The combined estimates cover pathogens across the list, not just those four urgent threats.
The report also identifies several changes. Drug-resistant Neisseria meningitidis is now classified as a serious threat requiring prompt and sustained action. Drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria have joined the watch list, which includes potential threats whose disease burden is uncertain.
Clostridioides difficile moved down from urgent to serious. The report links the change in part to infection-prevention measures that have reduced cases since 2011. That shift does not mean the infection is no longer a threat; it reflects a change in the agency’s classification.
The Cost of Drug Resistance
The annual estimates show the scale of infections and deaths associated with the pathogens the CDC tracks. Drug resistance can make infections harder to treat, and the effects extend beyond the illness itself. Wendy Armstrong, president of the Infectious Diseases Society of America, said resistant infections can prolong hospital stays and increase health-care costs.
Armstrong also warned that these infections can complicate care such as cancer chemotherapy, organ transplants and surgery, where infection risks and effective treatment options matter. The report’s categories may help public health officials and clinicians identify where prevention, monitoring and new treatments are needed. The overall figures are estimates, rather than a count of deaths recorded in one specific year.
Products Worth Considering

Levoit Core 300S-P Smart WiFi Air Purifier for Home and Pets

Withings Body Scan Smart Scale

Philips Sonicare ProtectiveClean 5300 Rechargeable Electric Toothbrush with 3 Brush Heads, Black
As an affiliate, we earn on qualifying purchases.
What the Urgent List Includes
The report highlights different risks across the four urgent pathogens. Candida auris is a multidrug-resistant yeast that can cause severe infections, particularly in people who are already seriously ill. Reported U.S. cases rose from 48 in 2016 to 4,523 in 2023, according to the source report.
Carbapenem-resistant Acinetobacter and Enterobacterales can cause infections in patients receiving hospital or nursing-home care, and treatment options may be limited. In 2023, the source reports, Acinetobacter was associated with 9,497 U.S. hospitalizations and an estimated 817 deaths; carbapenem-resistant Enterobacterales was associated with 14,878 hospitalizations and an estimated 1,252 deaths. These are pathogen-specific figures for 2023, distinct from the CDC’s combined annual estimate for all listed pathogens.
Drug-resistant gonorrhea can make treatment more difficult. The source report says it caused an estimated 787,000 U.S. infections in 2023, and 55.4% of cases that year were resistant to at least one of six antibiotics or had elevated minimum inhibitory concentrations. The FDA approved gepotidacin and zoliflodacin in 2025 as new antibiotics for gonorrhea, according to the report.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Annual Estimates
The CDC’s 50,800-death estimate is presented as the combined annual toll of the pathogens covered by the report. The source material does not specify the precise time period or calculation method behind that combined estimate, so it should not be read as a confirmed count of deaths in 2026. The report’s watch-list additions also carry uncertain disease burdens and are described as potential threats, not as established urgent threats.
The material provided does not include the full report’s methods, individual estimates for every pathogen or a detailed explanation of how the agency assigned each category. It is also unclear from the available information whether the latest figures change the CDC’s estimate of the total burden compared with its prior report.
Policy and Surveillance Ahead
The CDC’s updated classifications provide a new basis for tracking resistant infections and identifying pathogens that may need closer monitoring. The report does not announce a specific implementation timetable or new federal funding tied to the list.
Armstrong called for passage of the PASTEUR Act, which would establish a federal program to support development of antimicrobial drugs for threatening pathogens and infections. According to the source report, versions of the bill remain stalled in congressional committees. Whether Congress will advance the legislation, and what steps health agencies will take in response to the revised list, remain open questions.
Key Questions
What does the CDC estimate the pathogens cause each year?
The agency estimates that the pathogens in its updated report collectively cause 9.7 million infections and 50,800 deaths annually in the United States. The source material does not specify the exact period or method behind the combined estimate.
Which pathogens received the urgent classification?
The four drug-resistant pathogens identified as urgent threats are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Does C. difficile no longer pose a serious threat?
No. C. difficile moved from urgent to serious in the revised list. The report attributes the change in part to infection-prevention measures and fewer cases since 2011, but still classifies it as a serious threat.
What does it mean to be on the CDC watch list?
The watch list covers potential threats with uncertain disease burdens. Its inclusion does not mean a pathogen has been classified as an urgent threat.
Source: medpagetoday.com
